[Pharmacological consequences of the targeting of epidermal growth factor receptor].

Abstract:

:Through clearly identified molecular mechanisms, EGFR targeting leads to cell physiology modifications as cell proliferation, apoptosis and DNA repair. These mechanisms can explain the proper activity of EGFR targeting drugs but also represent a strong rational basis on which several experimental studies have been designed with combinations of EGFR targeting and cytotoxic agents (chemotherapeutic drugs and radiotherapy). These data led to the development of clinical trials combining EGFR targeting agents and anticancer drugs. There is however a lack of experimental data concerning the importance of the drug sequences and above all the impact of EGFR tumoral expression on the effects of combinations. The lack of knowledge on resistance mechanisms to EGFR targeting is also a difficulty for an optimal development of EGFR targeting in the clinics.

journal_name

Bull Cancer

journal_title

Bulletin du cancer

authors

Milano G,Magné N

subject

Has Abstract

pub_date

2003-11-01 00:00:00

pages

S197-201

eissn

0007-4551

issn

1769-6917

journal_volume

90 Spec No

pub_type

杂志文章,评审
  • [External beam radiation therapy and interstitial brachytherapy in the treatment of anal canal carcinomas: a series of 70 patients].

    abstract::This study is concerning 70 patients (57 female, 13 male) with an epidermoid carcinoma of the anal canal which were treated homogeneously with a combination of an external beam radiation therapy ((45 Gy in 25 fractions of 1.8 Gy for 5 weeks) and a brachytherapy with Iridium wires (15 to 20 Gy delivered to the gross re...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Dubois JB,Azria D,Ychou M

    更新日期:2003-12-01 00:00:00

  • Evaluation of multidrug resistant phenotype by flow cytometry with monoclonal antibodies and functional tests.

    abstract::Multidrug resistant (MDR) phenotype is characterized by a defect in drug accumulation caused by overexpression of a transmembrane glycoprotein, the P-glycoprotein (P-gp). MDR phenotype can be characterized either with monoclonal antibodies raised against P-gp or with functional tests, most often based on the incorpora...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Lizard G,Maynadié M,Roignot P,Lizard-Nacol S,Poupon MF

    更新日期:1995-03-01 00:00:00

  • [Update on docetaxel and breast cancer].

    abstract::Docetaxel (Taxotère) has been developed in breast cancer during the last decade. First its activity in monotherapy was proven in metastatic setting after failure of anthracycline therapy. Then the association with anthracycline demonstrated substantial activity leading to its development in early stages of breast canc...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Diéras V,Girre V,Pierga JY,Laurence V,Piperno-Neumann S,Pouillart P

    更新日期:2004-05-01 00:00:00

  • [Renal failure after allogeneic hematopoietic stem cell transplantation: Recommendations of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)].

    abstract::Acute and chronic renal failures are very common after allogeneic HSCT. These complications have a real impact on mortality and morbidity of transplant recipients. Within the framework of the ninth workshops of practice harmonization of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-...

    journal_title:Bulletin du cancer

    pub_type: 共识发展会议,杂志文章,实务指引

    doi:10.1016/j.bulcan.2019.05.002

    authors: Detrait M,de Berranger E,Dulery R,Ménard AL,Thépot S,Toprak SK,Turlure P,Yakoub-Agha I,Guillaume T

    更新日期:2020-01-01 00:00:00

  • [Imatinib in the treatment of chronic myeloid leukemia in Morocco].

    abstract:INTRODUCTION:The treatment of chronic myeloid leukemia (CML) has been revolutionized by the advent of tyrosine kinase inhibitors. The results of the IRIS trial demonstrated the efficacy and long-term safety profile of Imatinib. The objective of our work is to report the results at 15 years of treatment of CML in chroni...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1016/j.bulcan.2020.05.013

    authors: Dakkoune M,Qachouh M,Zoukal S,Hassoune S,Khoubila N,Cherkaoui S,Lamchahab M,Rachid M,Madani A,Quessar A

    更新日期:2020-09-01 00:00:00

  • [DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].

    abstract::Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in France. Recently, colorectal cancer subtyping consortium (CRCSC) identified 4 consensus molecular subtypes (CMS). CMS1 is enriched for CRC with deficient DNA mismatch repair system (dMMR) and tumors with mutated BRAF. Intriguingly, CMS1...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1016/S0007-4551(15)31220-0

    authors: Cohen R,Cervera P,Svrcek M,Dumont C,Garcia ML,Chibaudel B,de Gramont A,Pocard M,Duval A,Fléjou JF,André T

    更新日期:2015-06-01 00:00:00

  • [Limitations of palliative chemotherapy, application to lung cancer: the point of view of hospital pharmacists].

    abstract::In our hospital, most of the patients with a cancer received palliative chemotherapy. Then, we wanted to know in which conditions these therapies were realised and most specially for patients with lung cancer. We noted the stage of the disease at the diagnosis, the median survival duration after diagnosis and the medi...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Demange C,Thiébaux I

    更新日期:2003-03-01 00:00:00

  • [Genetic counseling in cancerology].

    abstract::The evidence that genetic factors are of some importance in the etiology of cancer originates has been determined by genetic epidemiology, molecular biology, cytogenetics. Genetic counselling is one of the possible strategies for controlling cancer through genetics. Genetic counselling in this field more often concern...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Feingold J

    更新日期:1991-01-01 00:00:00

  • [Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].

    abstract::Serotonin (5-Hydroxytryptamine) seems to play a dominant role in triggering vomiting induced by cytotoxic agents through the stimulation of 5-HT3 receptors. They have been observed in the GI tract as well as in the brain (area postrema). Ondansetron is a specific antagonist of 5-HT3 serotonin receptors. Its anti-emeti...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: d'Allens H,Aubert B,Bons J,Pappo M

    更新日期:1991-01-01 00:00:00

  • ARLTS1, potential candidate gene in familial aggregation of hematological malignancies.

    abstract:INTRODUCTION:Genetic predisposition to familial hematological malignancies was previously described through several epidemiological analyses, but the genetic basis remains unclear. The tumor-suppressor ARLTS1 gene was previously described in sporadic hematological malignancies and familial cancer context. METHODS:In t...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1016/j.bulcan.2016.10.016

    authors: Hamadou WS,Besbes S,Mani R,Bourdon V,Ben Youssef Y,Achour B,Regaieg H,Eisinger F,Mari V,Gesta P,Dreyfus H,Bonadona V,Dugast C,Zattara H,Faivre L,Noguchi T,Khélif A,Sobol H,Soua Z

    更新日期:2017-02-01 00:00:00

  • [Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of relapsing or refractory aggressive malignant lymphoma. Study of 51 patients].

    abstract::Fifty-one patients with non-Hodgkin's lymphoma refractory or relapsing after CHOP-like regimen, underwent a salvage chemotherapy by VPH: etoposide 100 mg/m2/d, D1 to D3, cisplatin 20 mg/m2/d, D1 to D5, ifosfamide 1 g/m2/d D1 to D5, mesna 1.2 g/m2/d D1 to D5, every 4 weeks. Among 46 evaluable patients for efficacy, 21 ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Eghbali H,Catry-Thomas I,Soubeyran P,Bonnel C,Hoerni B

    更新日期:1994-09-01 00:00:00

  • [News of the year 2005 in sarcomas].

    abstract::This year, the innovations were numerous in sarcomas. Important progress were accomplished in the search for predictive factors which make it possible to propose to the patient a personalized treatment with the therapeutic ones reduced in the event of good prognosis or on the contrary aggressive steps in the event of ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Fayette J,Méeus P,Sunyach MP,Thiesse P,Ray Coquard I,Blay JY

    更新日期:2006-01-01 00:00:00

  • [Radioimmunotherapy of follicular lymphoma: a step towards cure?].

    abstract::Advanced stage follicular lymphoma is incurable by conventional treatment. Important progress has been observed with the development of new therapies based on monoclonal antibodies and on the use of radioimmunotherapy (RIT) in the treatment of non-Hodgkin lymphomas (NHL). Rituximab in combination with chemotherapy in ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Ketterer N,Bischof Delaloye A,Helg C,Luthi F,Buchegger F

    更新日期:2007-09-01 00:00:00

  • [Rare cancers and new radiotherapy techniques].

    abstract::Rare cancers represent about a quarter of all cancers diagnosed in Europe, and their incidence is increasing. Meanwhile, scientific advances provide techniques, which become more and more sophisticated in the domain of radiotherapy. Treatment options for radiotherapy rare cancers are increasing, but are not yet evalua...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1016/j.bulcan.2014.12.001

    authors: Espenel S,Trone JC,Vallard A,Guy JB,Moriceau G,Méry B,Langrand-Escure J,Rivoirard R,de Laroche G,Chargari C,Magné N

    更新日期:2015-01-01 00:00:00

  • [Treatment of metastatic kidney neoplasms with a new interleukin 2 protocol: The experience of the Gustave-Roussy Institute].

    abstract::Treatment of metastatic renal cell carcinoma with interleukin 2 (IL2) remains controversial despite the authorization from the French government for IL2 with the West schedule in this disease. We report herein the study of the Institute Gustave-Roussy of 73 patients, who received from 1989 to 1991 a new schedule of hi...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Escudier B,Farace F,Théodore C,Angevin E,Court B,Couanet D,Dietrich PY,Culine S,Pallardy M,Hercend T

    更新日期:1995-04-01 00:00:00

  • [Chemotherapy combining vindesine, thiotepa and methotrexate in metastatic breast cancer after failure of a combination containing anthracycline. Results of a prospective phase II trial].

    abstract::Twenty-six patients with metastatic breast cancer where treated, after failure of a first line chemotherapy including an anthracycline, with a second line combination of vindesine, methotrexate and thiotepa. Overall tolerance of this treatment was good. There were one complete response and two partial responses. The a...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Comoz M,Chevallier B,Bastit P

    更新日期:1988-01-01 00:00:00

  • [Role of the epithelial-mesenchymal transition during tumor progression].

    abstract::The epithelial-mesenchymal transition (EMT) is a morphogenetic program that converts epithelial into mesenchymal cells during the embryonic development. This mechanism is frequently reactivated during tumor progression and provides cells with motility and invasive capabilities favoring the metastatic dissemination fro...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2009.1025

    authors: Ansieau S,Caron de Fromentel C,Bastid J,Morel AP,Puisieux A

    更新日期:2010-01-01 00:00:00

  • [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].

    abstract::Neuroblastoma is the most common pediatric extracranial solid cancer. Patients with metastatic disease at initial diagnosis who are greater than 18  months of age and patients with MycN amplified locoregional tumors are treated with intensive multimodal therapy. While this intensive approach has been shown to improve ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2011.1353

    authors: Défachelles AS,Cougnenc O,Carpentier P

    更新日期:2011-05-01 00:00:00

  • [Prostate cancer and chemotherapy].

    abstract::Androgen deprivation in patients with metastatic prostate cancer produces palliation of symptoms, PSA decrease and tumoral regression in most patients. After a brief period of disease regression lasting 18 to 24 months nearly all pts will progress to androgen independence disease (HRPC) with progressive clinical deter...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Gravis G,Salem N,Bladou F,Viens P

    更新日期:2007-07-01 00:00:00

  • [The value of MRI in the diagnosis of joint involvement in malignant primitive tumors of the knee].

    abstract:INTRODUCTION:Surgical treatment of malignant primitive tumors of bone needs a precise preoperative assessment of tumor local extension. Joint involvement (JI) represents the most important finding to determine, for the choice of surgical procedure (intra- or extra-articular resection). OBJECTIVE:To determine the value...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.bulcan.2016.09.018

    authors: Chelli Bouaziz M,Riahi H,Mechri M,Abid L,Rafaa M,Ladeb MF

    更新日期:2016-11-01 00:00:00

  • [The cost of radiotherapy].

    abstract::The higher human and material costs induced by the development of conformal radiotherapy and other innovative techniques have to be evaluated. Different studies reflect benefit for three-dimensional conformal radiation therapy. This needs appropriate economic analyses (cost/benefit, cost/utility). Conclusions from stu...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Martin P

    更新日期:2003-11-01 00:00:00

  • Infectious complications associated with granulocytopenia during the treatment of poor risk or relapsed germ cell tumors.

    abstract::Infectious complications associated with granulocytopenia during the treatment of poor risk or relapsed germ cell tumors were studied in order to assess the frequency, morbidity and characteristics of these complications. Thirty-three cases were investigated at the Institut Gustave-Roussy; 63 episodes of granulocytope...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Ribrag V,Droz JP,Kattan J,Andremont A

    更新日期:1992-01-01 00:00:00

  • [Oncolor is ten years old: the age of discretion for the Lorraine network in oncology].

    abstract::Oncolor, network in oncology in Lorraine, was born ten years ago, from a group of professionals in the field of oncology who worked closed together with regional administrative authorities. Oncolor was created with respect of equilibrium between the different regional partners avoiding struggle for power. Oncolor was ...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Bey P,Bouvier R,David M,Delena G,Garin H,Kessler Y,Klein I,Krakowski I,Lang MP,Leclercq JM,Level MC,Luron R,May I,Nabet M,Ruck S,Sommelet D,Theobald S,Unvois R,Walter S

    更新日期:2004-07-01 00:00:00

  • [Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer].

    abstract::Breast cancer is the most common cancer among women with more than 53,000 new cases every year in France. The PI3K/AKT pathway is one of the major pathways involved in mammary tumorigenesis. The first effector of this pathway downstream Human Epidermal growth factor Receptor (HER receptors) is the enzyme phosphatidyl-...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:10.1684/bdc.2013.1827

    authors: Harlé A,Lion M,Lozano N,Merlin JL

    更新日期:2013-10-01 00:00:00

  • [IMiDs in hematology].

    abstract::IMiDs belong to a new pharmalogical class, whose principal therapeutic agents are the thalidomide and the lenalidomide. They have immunomodulatory and antiangiogenic properties, as well as a direct effect on tumor cells. Thalidomide and lenalidomide were first approved for multiple myeloma, and in 5q-myelodysplastic s...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2011.1404

    authors: Wémeau M,Gauthier J,Leleu X,Yakoub-Agha I

    更新日期:2011-08-01 00:00:00

  • [Neoadjuvant approach for non-metastatic rectal cancer combining radiotherapy and chemotherapy. Biotargeted drugs].

    abstract::Neoadjuvant chemoradiotherapy is considered at the present time as the standard treatment of most T3-4 rectal cancer. In France a combination of radiotherapy (45 Gy/5 weeks) with concurrent capecitabine (1,600 mg/m2) is the most popular protocol. Randomized trials try to optimize this approach using new cytotoxic drug...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:10.1684/bdc.2009.0838

    authors: Gérard JP,Francois E,Deustch E,Rostom Y,Douar N,Benezery K,Milano G

    更新日期:2009-03-01 00:00:00

  • [10-year retrospective analysis of the sequelae of loco-regional treatment of breast cancer].

    abstract::With a minimum follow-up period of 10 years, the incidence of sequelae after loco-regional treatment of 349 breast cancers remains low, being dominated by lymphoedema. Rare after treatment by irradiation alone, lymphoedema appears more frequently in patients treated by radio-surgical association, in spite of a moderat...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Calitchi E,Cheula JM,Otmezguine Y,Roucayrol AM,Mazeron JJ,Le Bourgeois JP,Pierquin B

    更新日期:1984-01-01 00:00:00

  • [Recognition of occupational cancers: review of existing methods and perspectives].

    abstract::Occupational risk factors represent a significant part of cancer causes and are involved in all type of cancers. Nonetheless, the frequency of these cancers is largely under-estimated. Parallel to the epidemiological approach (collective), the concept of occupational cancer is often linked (at the individual level) to...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Vandentorren S,Salmi LR,Brochard P

    更新日期:2005-09-01 00:00:00

  • [Inhibitors of bone marrow stem cells proliferation. Possible applications during chemotherapy (author's transl)].

    abstract::An inhibitor of bone marrow stem cell (CFU-S) proliferation, prepared from fetal calf marrow, was administered to mice during sequential treatments with Cytosine Arabinoside. Results show that the percentage of CFU-S survival is significantly increased when the inhibitor is given simultaneously with the drug. A purifi...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章

    doi:

    authors: Guigon M,Frindel E

    更新日期:1981-01-01 00:00:00

  • [Cancer of the uterine cervix in young women. A retrospective study of 337 cases].

    abstract::A retrospective study of 337 cases of cervix cancers in women aged 35 years and under, treated between 1980-1990 at the Ibn Rochd Oncology Center in Casablanca, was analyzed in order to determine the main characteristics of this disease and the influence of age on prognosis. The incidence of these cases was stable thr...

    journal_title:Bulletin du cancer

    pub_type: 杂志文章,评审

    doi:

    authors: Acharki A,Sahraoui S,Benider A,Tawfiq N,Jouhadi H,Bouras N,Samlali R,Kahlain A

    更新日期:1997-04-01 00:00:00